EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave

Lolita Sasset, Roberta Angioni, Nicolò Presa, Ricardo Sánchez-Rodríguez, Claudia Cozzolino iD, Nicole Bertoldi, Serena Marinello, Monica Loy, Maria Mazzitelli, Federico Rea, Annamaria Cattelan iD, Barbara Molon iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Lolita Sasset und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Unit, University Hospital of Padua, 35128 Padua, Italy. Hauptthemen laut MEDLINE: COVID-19, Lung Transplantation, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Città della Speranza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung transplant recipients are at increased risk of severe COVID-19 due to lifelong immunosuppressive therapy, which impairs both innate and adaptive immune responses. Identifying effective supportive therapies is essential for mitigating the heightened vulnerability of this population. This study investigated the effects of tixagevimab/cilgavimab, a monoclonal antibody therapy, as pre-exposure prophylaxis (PrEP) in this population. A prospective study was conducted on 19 lung transplant recipients at Padua University Hospital, Italy, during the Omicron variant wave (May–June 2022). Participants received tixagevimab/cilgavimab intramuscularly and were monitored for 180 days. SARS-CoV-2-specific antibody levels were measured at baseline (T0), one month (T1), and three months (T3) post-treatment. Cytokine profiles and clinical outcomes, including SARS-CoV-2 infections, were also assessed. At baseline, 50% of patients had negative antibody responses, but one-month post-treatment, all patients exceeded 700 kBAU/mL (median 3870 kBAU/mL), with levels decreasing but remaining positive at three months (median 1670 kBAU/mL). Remarkably, a higher level of circulating IL-18 was found at T3 in comparison to T0 in patients who did not experience COVID-19 after PrEP. This finding aligns with IL-18’s primary role in stimulating type-1 T helper (Th1) cell responses, necessary for the induction of virus-specific cytotoxic T lymphocytes (CTLs). These results suggest that tixagevimab/cilgavimab may induce a systemic immune signature that could contribute to priming the immune response against SARS-CoV-2, potentially mediated by interactions with immune cell subsets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Lung TransplantationPre-Exposure ProphylaxisHumansFemaleMaleMiddle AgedSARS-CoV-2AgedProspective StudiesAntibodies, ViralAdultTransplant RecipientsAntibodies, Monoclonal, HumanizedItalyCytokinesCOVID-19 Drug Treatment

Stichwörter der Autor:innen

SARS-CoV-2immune responselung transplant recipientstixagevimab/cilgavimab

Substanzen

Antibodies, ViralAntibodies, Monoclonal, HumanizedCytokines

Autor:innen und Institutionen

  • Infectious and Tropical Diseases Unit, University Hospital of Padua, 35128 Padua, Italy.
  • Department of Biomedical Sciences, University of Padua, 35131 Padua, Italy.
  • Fondazione Istituto di Ricerca Pediatrica-Città della Speranza, 35127 Padua, Italy.
  • Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University Hospital of Padua, 35128 Padua, Italy.
  • Department of Molecular Medicine, University of Padua, 35131 Padua, Italy.

ORCID-Profile: Claudia Cozzolino, Annamaria Cattelan, Barbara Molon

Förderung

  • Fondazione Città della Speranza

Zitieren

APA

Sasset, L., Angioni, R., Presa, N., Sánchez-Rodríguez, R., Cozzolino, C., Bertoldi, N., Marinello, S., Loy, M., Mazzitelli, M., Rea, F., Cattelan, A., & Molon, B. (2025). Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083696

Vancouver

Sasset L, Angioni R, Presa N, Sánchez-Rodríguez R, Cozzolino C, Bertoldi N, et al. Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083696

BibTeX
@article{Sasset2025,
  author = {Sasset, Lolita and Angioni, Roberta and Presa, Nicolò and Sánchez-Rodríguez, Ricardo and Cozzolino, Claudia and Bertoldi, Nicole and Marinello, Serena and Loy, Monica and Mazzitelli, Maria and Rea, Federico and Cattelan, Annamaria and Molon, Barbara},
  title = {Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083696}
}
Kostenlos starten →